Molecular 'rehabilitation' by rational drug targeting: The challenge of p53 in cancer treatment

Anticancer Research

Volumn 19, Issue 5 B, 1999, Pages 4353-4356

  Tzatsos, Alexandros ^a   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Cancer treatment; p53 targeting; Rational drug design; Tumor suppressor

Indexed keywords

PROTEIN P53;

APOPTOSIS; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; DNA DAMAGE; DRUG DESIGN; DRUG TARGETING; HOMEOSTASIS; PRIORITY JOURNAL; REVIEW;

EID: 0032806386     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Levine AJ: p53, the cellular gatekeeper of growth and division. Cell 88: 323-331, 1997.
2. Bray SE, Schorl C and Hall PA: The challenge of p53: linking biochemistry, biology, and patient management. Stem Cells 16(4): 248-260, 1998.
3. De Vries EMG, Ricke DO, De Vries TN, Hartmann A, Blaszyk H, Liao D, Soussi T, Kovach JS and Sommer SS: Database of mutations in the p53 and APC tumor suppressor genes designed to facilitate molecular epidemiological analyses. Hum Mutat 7: 202-213, 1996.
4. Pietenpol JA, Tokino T, Thiagalingam S, el-Deiry WS, Kinzler KW and Vogelstein B: Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA 91: 1998-2002, 1994.
5. Cho Y, Gorina S, Jeffrey PD and Pavletich NP: Crystal structure of a p53 tumour suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355, 1994.
6. Gubernator K and Böhm HJ: Rational design of bioactive molecules. In: Structure-based ligand design (Gubernator K and Böhm HJ, eds). Weinheim, Wiley-VCH, 1998, pp 1-13.
7. Clore GM, Omichinski JG, Sakaguchi K, Zambrano N, Sakamoto H, Appella E and Gronenborn AM: High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science 265: 386-391, 1994.
8. Haffner R and Oren M: Biochemical properties and biological effects of p53. Curr Opin Genet Dev 5: 84-90, 1995.
9. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ and Pavletich NP: Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953, 1996.
10. McCoy M, Stavridi ES, Waterman JL, Wieczorek AM, Opella SJ and Halazonetis TD: Hydrophobic side-chain size is a determinant of the three-dimensional structure of the p53 oligomerization domain. EMBO J 16: 6230-6236, 1997.
11. Papavassiliou AG: Transcription-factor-modulating agents: precision and selectivity in drug design. Mol Med Today 4: 358-366, 1998.
12. Hupp TR, Sparks A and Lane DP: Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83: 237-245, 1995.
13. Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, Grafstrom RC and Wiman KG: Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 3: 632-638, 1997.
14. Kauvar LM: Peptide mimetic drugs: a comment on progress and prospects. Nat Biotechnol 14: 709, 1996.
15. Moll UM, Riou G and Levine AJ: Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 89: 7262-7266, 1992.
16. Moll UM, LaQuaglia M, Benard J and Riou G: Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 92: 4407-4411, 1995.
17. Bandara LR, Girling R and La Thangue NB: Apoptosis induced in mammalian cells by small peptides that functionally antagonize the Rb-regulated E2F transcription factor. Nat Biotechnol 15: 896-901, 1997.
18. Oliner JD, Kinzler KW, Meltzer PS, George DL and Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83, 1992.
19. Momand J, Zambetti GP, Olson DC, George D and Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992.
20. Kubbutat MHG and Vousden KH: Keeping an old friend under control: regulation of p53 stability. Mol Med Today 4: 250-256, 1998.
21. Kubbutat MHG and Vousden KH: Role of E6 and E7 oncoproteins in HPV-induced anogenital malignancies. Semin Virol 7: 295-304, 1996.
22. Shieh SY, Ikeda M, Taya Y and Prives C: DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334, 1997.
23. Juven-Gershon T and Oren M: Mdm2: the ups and downs. Mol Med 5: 71-83, 1999.